THE TRANSLATIONAL GENOMICS RES INST has a total of 24 patent applications. It decreased the IP activity by 100.0%. Its first patent ever was published in 2013. It filed its patents most often in United States, WIPO (World Intellectual Property Organization) and EPO (European Patent Office). Its main competitors in its focus markets biotechnology, pharmaceuticals and measurement are TRANSLATIONAL GENOMICS RES INST, POPULATION BIO INC and INST OF ANIMAL HEALTH GUANGDONG ACAD OF AGRICULTURAL SCIENCES.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 12 | |
#2 | WIPO (World Intellectual Property Organization) | 11 | |
#3 | EPO (European Patent Office) | 1 |
# | Industry | |
---|---|---|
#1 | Biotechnology | |
#2 | Pharmaceuticals | |
#3 | Measurement | |
#4 | Organic fine chemistry | |
#5 | Environmental technology | |
#6 | Computer technology |
# | Name | Total Patents |
---|---|---|
#1 | Keim Paul | 4 |
#2 | Engelthaler David | 4 |
#3 | Huentelman Matthew | 4 |
#4 | Craig David | 4 |
#5 | Carpten John | 3 |
#6 | Bowers Jolene | 3 |
#7 | Driebe Elizabeth | 3 |
#8 | Wang Tong | 2 |
#9 | Azorsa David | 2 |
#10 | Van Keuren-Jensen Kendall | 2 |
Publication | Filing date | Title |
---|---|---|
WO2016164719A2 | Methods used to treat cancer | |
US2015323538A1 | Systems and methods for diagnosing and treating cancer | |
US2016146784A1 | Method of screening for a compound for inhibitory activity of FN14-tweak interaction | |
US2016017027A1 | Hybridoma clones and monoclonal antibodies to fibroblast growth factor 4 |